Cardiac toxicity of HER-2 targeting antibody-drug conjugates: overview and clinical implications.
Future Oncol
; : 1-17, 2024 Oct 07.
Article
em En
| MEDLINE
| ID: mdl-39373602
ABSTRACT
Antibody-drug conjugates (ADCs) have recently emerged as a promising therapeutic option that combine the specificity of monoclonal antibodies and the cytotoxic effect of chemotherapy. With numerous ADCs approved and on the market, a particular concern of ADCs that target HER-2 has been their cardiac side effects, in view of the crucial role of HER-2 in cardiac development and physiology. While rarely toxic and generally safe, numerous publications have outlined the consistent association of trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) with the development of cardiac toxicity. Despite not being clinically relevant in most cases, cardiac baseline evaluation, monitoring and early detection of cardiac adverse events remain pivotal with HER-2 targeting ADCs. This review aims to summarize and better characterize the complete cardiac toxicity profile of HER-2 ADCs, with the goal of improving clinical understanding of this adverse event, leading to better recognition, monitoring and management.
[Box see text].
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Future Oncol
/
Future oncol
/
Future oncology
Ano de publicação:
2024
Tipo de documento:
Article
País de afiliação:
Líbano
País de publicação:
Reino Unido